| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials
|
Bangalore, Sripal
|
|
2011
|
12 |
1 |
p. 65-82
18 p.
|
artikel
|
| 2 |
Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial
|
Kitchener, Henry C
|
|
2011
|
12 |
1 |
p. 56-64
9 p.
|
artikel
|
| 3 |
Blood-pressure drugs and cancer: much ado about nothing?
|
Lindholm, Lars H
|
|
2011
|
12 |
1 |
p. 6-8
3 p.
|
artikel
|
| 4 |
Cetuximab in NSCLC: another trial needed
|
Perrone, Francesco
|
|
2011
|
12 |
1 |
p. 3-4
2 p.
|
artikel
|
| 5 |
China wrestles with lung cancer
|
Wen, Chihua
|
|
2011
|
12 |
1 |
p. 15-
1 p.
|
artikel
|
| 6 |
Dear Doctor
|
Burki, Talha
|
|
2011
|
12 |
1 |
p. 20-
1 p.
|
artikel
|
| 7 |
Drug interactions in childhood cancer
|
Haidar, Cyrine
|
|
2011
|
12 |
1 |
p. 92-99
8 p.
|
artikel
|
| 8 |
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
|
Cuzick, Jack
|
|
2011
|
12 |
1 |
p. 21-29
9 p.
|
artikel
|
| 9 |
EPCAM deletions, Lynch syndrome, and cancer risk
|
Lynch, Henry T
|
|
2011
|
12 |
1 |
p. 5-6
2 p.
|
artikel
|
| 10 |
Errata
|
|
|
2011
|
12 |
1 |
p. 11-
1 p.
|
artikel
|
| 11 |
Errata
|
|
|
2011
|
12 |
1 |
p. 11-
1 p.
|
artikel
|
| 12 |
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
|
Gatzemeier, Ulrich
|
|
2011
|
12 |
1 |
p. 30-37
8 p.
|
artikel
|
| 13 |
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
|
Kim, Richard
|
|
2011
|
12 |
1 |
p. 8-9
2 p.
|
artikel
|
| 14 |
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
|
Kloosterhof, Nanne K
|
|
2011
|
12 |
1 |
p. 83-91
9 p.
|
artikel
|
| 15 |
MET inhibitors: translating from bench to bedside
|
Mayor, Susan
|
|
2011
|
12 |
1 |
p. 14-
1 p.
|
artikel
|
| 16 |
52nd ASH annual meeting
|
Grainger, Emma
|
|
2011
|
12 |
1 |
p. 18-
1 p.
|
artikel
|
| 17 |
NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer
|
Holden, Joanne
|
|
2011
|
12 |
1 |
p. 16-17
2 p.
|
artikel
|
| 18 |
Rational individualised selection of adjuvant therapy for ductal carcinoma in situ
|
Kuerer, Henry M
|
|
2011
|
12 |
1 |
p. 2-3
2 p.
|
artikel
|
| 19 |
33rd San Antonio Breast Cancer Symposium
|
Dehnel, Tim
|
|
2011
|
12 |
1 |
p. 19-
1 p.
|
artikel
|
| 20 |
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study
|
Kempers, Marlies JE
|
|
2011
|
12 |
1 |
p. 49-55
7 p.
|
artikel
|
| 21 |
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort
|
Jacobs, Ian
|
|
2011
|
12 |
1 |
p. 38-48
11 p.
|
artikel
|
| 22 |
Should anthracyclines and dexrazoxane be used for children with cancer?
|
van Dalen, Elvira C
|
|
2011
|
12 |
1 |
p. 12-13
2 p.
|
artikel
|
| 23 |
Should we screen for endometrial cancer?
|
Vergote, Ignace
|
|
2011
|
12 |
1 |
p. 4-5
2 p.
|
artikel
|
| 24 |
Treatment non-adherence in teenage and young adult patients with cancer
|
Kondryn, Helena J
|
|
2011
|
12 |
1 |
p. 100-108
9 p.
|
artikel
|
| 25 |
US cancer care: should insurers really be in the driving seat?
|
The Lancet Oncology,
|
|
2011
|
12 |
1 |
p. 1-
1 p.
|
artikel
|
| 26 |
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib
|
Buclin, Thierry
|
|
2011
|
12 |
1 |
p. 9-11
3 p.
|
artikel
|
Tijdschrift beschrijving